Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 12 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humansWu, T.; Bound, M.; Standfield, S.; Gedulin, B.; Jones, K.; Horowitz, M.; Rayner, C.
2013Glucagon-like peptides 1 and 2 in health and disease: A reviewMarathe, C.; Rayner, C.; Jones, K.; Horowitz, M.
2013Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectivesStevens, J.; Jones, K.; Rayner, C.; Horowitz, M.
2013A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetesMa, J.; Checklin, H.; Wishart, J.; Stevens, J.; Jones, K.; Horowitz, M.; Meyer, J.; Rayner, C.
2013Relationships between gastric emptying, postprandial glycemia, and incretin hormonesMarathe, C.; Rayner, C.; Jones, K.; Horowitz, M.
2013Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetesWu, T.; Bound, M.; Zhao, R.; Standfield, S.; Bellon, M.; Jones, K.; Horowitz, M.; Rayner, C.
2013Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humansWu, T.; Bound, M.; Standfield, S.; Jones, K.; Horowitz, M.; Rayner, C.
2013Mechanisms and clinical efficacy of lixisenatide for the management of type 2 DiabetesHorowitz, M.; Rayner, C.; Jones, K.
2013Diabetic gastroparesis: Recent insights into pathophysiology and implications for managementSebastian Thazhath, S.; Jones, K.; Horowitz, M.; Rayner, C.
2013Response to comment on: Chang et al. A 25-Year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care 2012;35:2594-2596Rayner, C.; Chang, J.; Jones, K.; Horowitz, M.